Form 4: Kura Oncology Director Receives Stock Option Grant

Director Carol Schafer was granted 35,000 stock options in Kura Oncology, Inc. as part of a standard equity compensation package.

Summary

• Director Carol Schafer acquired 35,000 options to purchase common stock in Kura Oncology, Inc.
• The options have an exercise price of $8.77 per share.
• The grant date is June 4, 2026, with an expiration date of June 3, 2036.
• The options vest in full on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Standard market risks associated with equity-based compensation and potential dilution.

Future Outlook

The options vest in full on June 4, 2027, aligning the director's interest with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of 35,000 options is consistent with typical annual equity compensation packages for independent directors in mid-cap oncology firms.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 4, 2027.

Key Dates

Keywords

Kura Oncology, KURA, Director Compensation, Stock Options, SEC Form 4, Insider Transaction